TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02674906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: use of heparin as anticoagulant after blood salvage during cardiac surgery
Study: NCT03361475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SME App
Description: The features in the App could be used in the future by linking with some platforms / existing services so that more SME messages can be sent to the students for sharing. One school workshop will be held to promote SME and introduce the function of SME App for students to download and use immediately to connect family members.~SME App promotes SME via:~* Express gratitude to family members (sharing)~* Deliver positive messages regularly (mind)~* Record physical and other joyful activities (enjoyment)~* Increase knowledge and understanding of adolescent mental health problem (in particular the anxiety disorders)
Study: NCT02338193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAPA/MET XR
Description: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
Study: NCT04541446

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Haptic Robotic Trainer (DHRT)
Description: Device trains medical residents to safely perform the needle insertion portion of Central Venous Catheterization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Dynamic Haptic Robotic Trainer (DHRT+)
Description: Device offers whole procedural training for medical residents to safely perform the procedure of Central Venous Catheterization.
Study: NCT02338193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPA
Description: 10 mg dapagliflozin QD for 20-24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MET XR
Description: 1000 mg Metformin XR BID for 20-24 weeks
Study: NCT01212588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: Mifepristone 600mg (3x200mg tablets) once daily for seven days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets once daily for seven days
Study: NCT03947320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation FVIII
Description: Participant received SCT800 for prophylaxis with 25 - 50 IU/kg injection once every other day or three times per week for 6 months.
Study: NCT03003390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given \<24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
Study: NCT02737098

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Implementation Strategy
Description: The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Implementation Strategy
Description: Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
Study: NCT02140372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 1.2 mg followed by 0.6 mg one hour later
Study: NCT00656383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clients randomized to nurse-led clinic
Description: Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clients receive leg ulcer care in their homes
Description: Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
Study: NCT00756756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion of normal saline
Description: 2 week post MI and PCI normal saline was infused
Study: NCT02376478

Intervention type: DRUG
Intervention: Alternative/no medication
Description: therapy for at least 6 months or no therapy

Intervention type: OTHER
Intervention: Alternative/no medication
Description: phototherapy for at least 6 months

Intervention type: DRUG
Intervention: Purine/folic acid analogues
Description: therapy for at least 6 months

Intervention type: DRUG
Intervention: Purine/folic acid analogues
Description: therapy for at least 6 months
Study: NCT03010904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Study: NCT03627000

Intervention type: OTHER
Intervention: failure after reimplantation
Description: description of cinical and microbiological failure
Study: NCT03628495

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: compression
Description: compression will be delivered using compression garment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compression
Description: compression will be delivered using compression garment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusion
Description: occlusion will be delivered using silicone gel sheeting
Study: NCT02680119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 40 mg DR Capsules of AstraZeneca LP, USA.
Description: oral, crossover

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Esomeprazole Magnesium DR Capsules 40 mg
Description: oral, crossover
Study: NCT02877316

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MYPLAN-safety plan as an application for smart phones
Description: MYPLAN app as a integral part of the standard treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: safety plan on paper
Description: Standard treatment with safety plan on paper
Study: NCT00410904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Study: NCT01624610

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
Study: NCT03260283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pethidine hydrochloride
Description: In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine HCl Inj 7.5 MG/ML
Description: In Group II patients will be administered with 2 ml of ropivacaine (0.75%)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations
Study: NCT01154738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia.~start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 9/00 (same volume as in the lidocaine group)~start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00
Study: NCT00759083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivalirudin
Description: Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
Study: NCT03960658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine-enhanced prolonged exposure
Description: Subjects will receive a single infusion of racemic ketamine at 0.5mg/kg (ideal body weight) for 40 minutes. The next day, patients will have a standardized prolonged exposure session which lasts approximately 90 minutes. This co-jointed intervention will be repeated for 3 weeks. Then, patients will continue with therapy sessions to complete a total of 10-12 sessions.
Study: NCT02175303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decidual stromal cell therapy
Description: Decidual stromal cells from placenta will be infused intravenously at approximately 1x10\^6 cells/kg at one or more occasions at weekly intervals.
Study: NCT02667392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gait Training with Biofeedback
Description: Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gait Training with Verbal Feedback
Description: Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.~Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation.
Study: NCT01119963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-alpha-hydroxy-progesterone caproate, Makena®
Description: Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Castor Oil (Placebo)
Description: IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
Study: NCT01039311

Intervention type: DEVICE
Intervention: Optical Coherence Tomography
Description: Obtain OCT images.
Study: NCT02411513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEFALY
Study: NCT04030468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention addressed to general practitioners
Description: * feedback reports regarding the status of their patients according to the appropriateness indicators determined at baseline and the pooled prevalences for their patients, Local Health Units, and region~* Continuous Medical Education (CME) course

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention addressed to general practitioners
Description: * feedback reports regarding the status of their patients according to the appropriateness indicators determined at baseline and the pooled prevalences for their patients, Local Health Units, and region~* Continuous Medical Education (CME) course

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informative intervention addressed to patients
Description: • leaflets and posters distributed in primary care ambulatories and community pharmacies, focusing on correct drug use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informative intervention addressed to patients
Description: • leaflets and posters distributed in primary care ambulatories and community pharmacies, focusing on correct drug use
Study: NCT04250025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
Description: 60 patients benefit from immediate venous angioplasty stenting plus medical treatment, i.e. elastic compression and anticoagulation
Study: NCT04319445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness session(s)
Description: The sessions will be hosted online using an online platform (such as through webex, private YouTube page, Facebook live, etc).
Study: NCT00519883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Study: NCT04645004

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 81Mg Non-enteric coated Tab
Description: one tab daily
Study: NCT03224104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02
Description: The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02
Description: The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02
Description: The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.~The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: For group A standard involved-field hypofractionated RT will be administered at 39.9 Gy in 15 fractions of 2.66 Gy for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
Study: NCT03771781

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin Tablets
Description: Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets.

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin Tab 25 MG
Description: Observe the safty and PK after subjects receiving a single dose of Empagliflozin Tablets( Jardiance®）.
Study: NCT04401085

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 diagnostic rapid test
Description: The rapid test detects the presence of antibodies against SARS-CoV-2 in the IgM and IgG class by the immunochromatographic reaction. It cannot detect early infection, the antibodies will probably appear two weeks after possible infection. The collection will be performed by finger puncture.

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 diagnostic rapid test
Description: The rapid test detects the presence of antibodies against SARS-CoV-2 in the IgM and IgG class by the immunochromatographic reaction. It cannot detect early infection, the antibodies will probably appear two weeks after possible infection. The collection will be performed by finger puncture.

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 diagnostic rapid test
Description: The rapid test detects the presence of antibodies against SARS-CoV-2 in the IgM and IgG class by the immunochromatographic reaction. It cannot detect early infection, the antibodies will probably appear two weeks after possible infection. The collection will be performed by finger puncture.
Study: NCT01496144

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy and active exercises
Description: Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.~Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises
Study: NCT04401085

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative analysis of SARS-CoV-2 antibodies
Description: The subsample from Olomouc region (Olomouc, Uničov, Litovel) is based on venous blood sampling and archiving for subsequent quantitative analysis of SARS-CoV-2 antibodies. These tests detect immunoglobulins M and G (IgM and IgG).
Study: NCT01496144

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Detuned ultrasound and active exercises
Description: Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
Study: NCT03476967

Intervention type: PROCEDURE
Intervention: Panretinal photocoagulation
Description: In cases of proliferative diabetic retinopathy (PDR), panretinal photocoagulation (PRP) is the first-line treatment. Although PRP reduces the risk of severe vision loss, it has been shown that laser energy can cause destruction to all layers of retina including the ganglion cells and the retinal nerve fiber layer (RNFL), and therefore generate visual field defects similar to that observed in glaucomatous damage. In such cases, visual field testing can be less helpful to evaluate glaucomatous damage in PDR patients treated with PRP.
Study: NCT03788616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fuji IX EXTRA
Description: High-viscosity glass ionomer (Fuji IX EXTRA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACTIVA KIDS bioactive restorative material
Description: Modified composite (ACTIVA KIDS)
Study: NCT00621010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTS21166 (ZPQ-21166)
Description: Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion
Study: NCT00246376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: ATP-III diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: ATP-III diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: ATP-III diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: ATP-III diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise in study gym

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise in study gym

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise in study gym

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised exercise in study gym

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Niaspan, titrated up to 2 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin
Description: Niaspan, titrated up to 2 grams per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Tricor, 120 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Tricor, 120 mg per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos for Niaspan and Tricor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos for Niaspan and Tricor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos for Niaspan and Tricor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos for Niaspan and Tricor
Study: NCT02923050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Suppers
Description: Theory-based 10-week family meals program
Study: NCT00873145

Intervention type: PROCEDURE
Intervention: HMRS
Description: Modular prosthetic replacement of the humerus and elbow.
Study: NCT03932019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jitongning tablet(High-dose )
Description: Jitongning tablet,3tablets,bid,treat 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jitongning tablet(Low-dose )
Description: Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Jitongning tablet placebo,3tablets,bid,treat 12 weeks